PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsNew drug could help treat Down's syndrome

BioNews

New drug could help treat Down's syndrome

Published 23 November 2009 posted in News and appears in BioNews 535

Author

Dr Will Fletcher

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

A new drug that is being developed may lessen the effects of learning difficulties caused by the genetic condition Down's syndrome. Children with the condition are not developmentally delayed at birth, but often fall behind as they grow older because of memory deficits. A new study in mice, published in the journal Science Translational Medicine, has identified the key brain defects responsible and has pointed out a strategy for dealing with them through medication. The US resea...

A new drug that is being developed may lessen the effects of learning difficulties caused by the genetic condition Down's syndrome. Children with the condition are not developmentally delayed at birth, but often fall behind as they grow older because of memory deficits. A new study in mice, published in the journal Science Translational Medicine, has identified the key brain defects responsible and has pointed out a strategy for dealing with them through medication. The US researchers, from Stanford University School of Medicine and Lucile Packard Children's Hospital, have said that the medication could also help protect against early onset Alzheimer's disease, which is especially common in the middle aged Down's syndrome community. Both conditions are linked to the same gene, known simply as APP, but this new study is the first to directly link APP with the specific type of brain degeneration responsible for Down's syndrome.


Around 60,000 people in Britain are affected by Down's syndrome and there is currently no cure. The risk of having a baby with the condition is about 1 in 940 for a 30 year old woman, but closer to 1 in 85 for a 40 year old woman. The increasing average age of mothers has therefore meant that the number of conceptions of babies with Down's syndrome has increased dramatically in the past 20 years. However, there has been a parallel increase in screening and termination meaning that the overall proportion of babies born with the condition has remained roughly fixed at about 1 in 750. Down's syndrome is caused by an extra copy of chromosome 21, more specifically a second copy of the gene APP on chromosome 21.The condition is characterised by memory deficits that make it difficult for the brain to collect and process experiences. Forming new memories in this way underpins the development of learning and is crucial to normal cognitive development. This explains why those with Down's syndrome often fall behind, with children as young as 2 performing worse in basic cognitive tests. Most people with the condition survive into middle age, but exhibit symptoms similar to those of dementia around the ages of 50 to 60.


Normally when contextual and relational memories are formed neurons, in an area of the brain known as the hippocampus, receive the chemical norepinephrine from another area of the brain known as the locus coeruleus. The new study involved mice that were genetically engineered to mimic Down's syndrome in that, like humans with Down's syndrome, the mice had experienced early degeneration of the locus coeruleus. These engineered mice exhibited abnormal behaviour such as not building nests when placed in new and unfamiliar cages. However, when the engineered mice were given certain drugs (that were converted to norepinephrine in their brains) improvements were quickly noticed. Within hours they were just as good at nest building and showed improved performance in the other related tests. Further detailed examination of their brains showed that the hippocampal neurons had responded well to the treatment.


'We were very surprised to see that, wow, it worked so fast,' said Ahmad Salehi, leader of the study. However, he warned that the effect of the drugs also wore off quickly, and seemed to have disappeared altogether when the mice were tested two weeks later. Salehi added: 'If you intervene early enough you will be able to help kids with Down's syndrome to collect and modulate information.' Others involved are also optimistic. The findings give 'a ray of hope and optimism for the Down syndrome community for the future,' said Dr Melanie Manning, director of the Centre for Down’s syndrome at Lucile Packard Children's Hospital.


Although promising, research reported in the LA Times this week shows that not all parents would welcome the prospect of a cure for their child's Down's syndrome. In a survey carried out by scientists at the University of British Columbia in Vancouver, 27 per cent of parents said they would not cure their children, and another 32 per cent said they were unsure. 101 Canadian parents of children with Down's syndrome took part in the study, which was presented at the National Society of Genetic Counselors' annual education conference in Atlanta.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
19 July 2013 • 2 minutes read

Down's syndrome chromosome 'can be silenced'

by Dr Lucy Freem

A method that 'switches off' entire chromosomes has been used in isolated cells to target the genetic defect behind Down's syndrome...

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on Auguste Rodin's 'The Thinker').
CC BY 4.0
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1997. Depicts the gyri of the Thinker's brain as a maze of choices in biomedical ethics (based on the sculpture 'The Thinker' by Auguste Rodin).
News
13 December 2012 • 2 minutes read

Safer prenatal test for Down's syndrome launched in US

by Julianna Photopoulos

A new prenatal test that can detect Down's syndrome by using a sample of the mother's blood was launched in twenty US cities last Monday....

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Early genetic events in Down's syndrome revealed

by Dr Rebecca Robey

Scientists have discovered the earliest genetic changes that occur in Down's syndrome, resulting in the abnormal development of the foetus and eventually leading to the host of medical complications associated with the disorder. The findings, published in the American Journal of Human Genetics, are a step forward...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 June 2009 • 2 minutes read

Gene clue to Down syndrome dementia

by Dr Jess Buxton

US scientists have discovered that a key gene could trigger the mental impairment and early onset Alzheimer's disease associated with Down syndrome. The findings, reported in two papers published in the journal Neuron, show that the over-production of a gene involved in nerve growth can kill...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Five new genes linked to Parkinson's disease

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

27 June 2022 • 2 minutes read

UK report reveals public attitudes to fertility, genomics and embryo research

27 June 2022 • 2 minutes read

Shortage of sperm donors despite men willing to donate

27 June 2022 • 2 minutes read

North East London CCG proposes offering three funded IVF cycles

27 June 2022 • 2 minutes read

Fibrosis drugs reverse ovarian ageing in mice

27 June 2022 • 2 minutes read

Gene implicated in motor neurone diseases discovered

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856